Initiatives for developing and comparing genotype interpretation systems: External validation of existing systems for didanosine against virological response

Journal of Infectious Diseases

Volumn 198, Issue 4, 2008, Pages 470-480

  Assoumou, Lambert ^a,b   Brun Vézinet, Françoise ^c   Cozzi Lepri, Alessandro ^d   Kuritzkes, Daniel ^e   Phillips, Andrew ^d   Zolopa, Andrew ^g   DeGruttola, Victor ^f   Miller, Veronica ^h   Costagliola, Dominique ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; SAQUINAVIR PLUS RITONAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS LOAD;

ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 48749085588     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/590156     Document Type: Article

References (21)

1. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1 Infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 2005; 191:840-7.
2. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-44.
3. Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu/pages/asi/releaseNotes/.
4. Agence Nationale de Recherches sur le SIDA (ANRS). HIV-1 genotypic drug resistance interpretation's algorithms. Available at: http://www. hivfrenchresistance.org/table.html.
5. Laboratory for Clinical and Evolutionary Virology. The Rega algorithms. Available at: http://www.rega.kuleuven.be/cev/index.php?id=30.
6. International AIDS Society-USA Web site. Available at: http://www.iasusa.org/resistance_mutations/index.html.
7. Advanced Biological Laboratories. Algorithm and Knowledgebase updates. Available at: http://www.ablsa.com/site/en/product_vs_algos.html.
8. MacArthur RD. An updated guide to genotype interpretation. AIDS Reader 2004; 14:256-66.
9. Flandre P, Marcelin AG, Pavie J, et al. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir Ther 2005; 10:479-87.
10. Brun-Vézinet F, Costagliola D, Ait Khaled M, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-78.
11. Ravela J, Betts BJ, Brun-Vézinet F, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003; 33:8-14.
12. Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003; 8:239-44.
13. Boulmé R, Halfon P, Diaz R, Dugas O, Schmit JC. Comparative evaluation between five automated resistance interpretation algorithms. Antivir Ther 2001; 6(Suppl 1):121.
14. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-9.
15. Van Laethem K, Witvrouw M, Balzarini J, et al. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS 2000; 14:469-71.
16. Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43:1961-7.
17. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41:757-62.
18. Forum for Collaborative HIV Research. Standardization and clinical relevance of HIV drug resistance testing. Available at: http://www.hivforum.org/ projects/standardization.html.
19. Kleinbaum D, Kupper L, Muller K. Applied regression analysis and other multivariable methods. 2nd ed. Belmont, CA: Duxbury Press, 1988.
20. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med 2000; 19:3171-91.
21. Costagliola D, Cozzi-Lepri A, Dalban C, Cheng B. Initiatives for developing and comparing genotype interpretation systems step 1: external validation of existing rules-based algorithm for abacavir and ddI evaluated on virological response. Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Antivir Ther 2005; 10(Suppl 1):S11.